AzurRx BioPharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AZRX research report →
About the company
AzurRx BioPharma, Inc. , a Brooklyn, New York-based company employing 12 full-time individuals, focuses on the discovery and advancement of non-systemic biological treatments for various gastrointestinal conditions. Its current developmental portfolio comprises two therapeutic protein assets: MS1819 and AZX1101.
- CEO
- James Sapirstein
- IPO
- 2016
- Employees
- 12
- HQ
- Brooklyn, NY, US
Price Chart
- Market Cap
- $3.43M
- P/E
- -0.73
- P/S
- 46.10
- P/B
- 0.65
- EV/EBITDA
- 3.11
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- -13264.41%
- Net Margin
- -11728.15%
- ROE
- -49.81%
- ROIC
- -28.86%
- Revenue
- $36.25K · 0.00%
- Net Income
- $-6,553,578 · 63.71%
- EPS
- $-4.16 · 21.95%
- Op Income
- $-7,083,438
- FCF YoY
- 38.13%
- 52W High
- $26.30
- 52W Low
- $2.68
- 50D MA
- $4.94
- 200D MA
- $7.50
- Beta
- 1.51
- Avg Volume
- 713.03K
Get TickerSpark's AI analysis on AZRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 9, 21 | Coelho Mary Theresa | other | 10,310 |
| Aug 11, 21 | Coelho Mary Theresa | other | 0 |
| Jul 9, 21 | Pennington James | other | 100,000 |
| Jun 30, 21 | Schneiderman Daniel H | other | 250,000 |
| Jun 30, 21 | Schneiderman Daniel H | other | 35,006 |
| Jun 30, 21 | Schneiderman Daniel H | other | 250,000 |
| Jun 30, 21 | SAPIRSTEIN JAMES | other | 900,000 |
| Jun 30, 21 | SAPIRSTEIN JAMES | other | 900,000 |
| Jan 4, 21 | Oakes Gregory | other | 41,237 |
| Jan 4, 21 | BORKOWSKI EDWARD | other | 41,237 |
Our AZRX coverage
Recent articles, reports, and earnings notes.
No research on AZRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AZRX report →Similar companies
Peers in the same neighborhood.